CategoryNews and events

Ocrelizumab’s known-unknowns

Below is the first case report of fulminant hepatitis owing to echovirus 25 in an MSers on ocrelizumab. Please note continuous anti-CD20 therapy takes out your B-cells and prevents you from forming germinal centres (where B-cells get educated to make antibodies, i.e. the B-cell’s Universities) in lymph nodes and the spleen. In other words, ocrelizumab treatment causes functional splenectomy...

Hepatitis post-alemtuzumab

Another alemtuzumab-related post, this time in relation to alemtuzumab-associated liver injury, which has been also been included as a complication of alemtuzumab treatment in the EMA’s SmPC (summary of product characteristics). Liver or hepatic injury can occur as part of a drug-induced injury as seen in case 2 below or as a delayed, presumably autoimmune, condition as in case 1 below...

Alemtuzumab use put on Restriction

The European Medicines Agency (EMA) has started a review of alemtuzumab following recet reoports of sde effects affecting the heart, blood vessels, liver and immune system.  These side effects are rare but potentially serious. As a temporary measure while the review is being carried out, the EMA has advised that alemtuzumab should only be started in people with relapsing remitting MS that...

Alemtuzumab’s Article 20

Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing EMA has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions (caused by the body’s defence system not working properly) and problems with the heart and blood vessels with the medicine, including fatal cases. As a temporary measure while the...

Guest post: Free online course now open!

Along with a great team from the Menzies Institute for Medical Research at the University of Tasmania (Australia) and Multiple Sclerosis Ltd., I have spent the past year building a 6-week online course about MS for the MS community and the general public. The course, entitled “Understanding MS”, has recently opened for enrolments and will begin on Monday 29 April 2019. The course presents up-to...

Raising the Bar

You may recall last year the MS Academy held a meeting to address variance in the provision of MS services in the NHS. This meeting was very well received and several follow-on initiatives have been triggered as a result of the meeting. The MS Academy is now hosting a follow-on meeting called ‘MS Service Provision in the UK 2019: Raising the Bar‘. If you want to read about what...

Health Vault: a failed experiment

Microsoft’s HealthVault promised to revolutionise the way medicine was done. The fact they are closing it down tells a story. Not enough vision and commitment. Very disappointing. Maybe the MS Brain Health consortium will do a better job with MS-Connect. What do you think? IMPORTANT NOTICE ABOUT YOUR MICROSOFT HEALTHVAULT SERVICE Microsoft HealthVault service to end November 20, 2019 This...

Coffee and chat today!

If you are a Barts-MS patient, make sure you head to Whitechapel for a new patient-led group – Coffee and a Chat. Bonnie and Elizabeth have set up this friendly support network for all patients of Barts-MS. Come along to the Nucleus cafe in the Blizard building in Whitechapel (E1 2AT) from 10am – 12pm on the first Friday of each month through 2019. The next one is today! Friday 5th April. So...

Translate

Categories

Recent Posts

Recent Comments

Archives